GlassScriptPhysician profile
Mohammed Maruf Qureshi
NPI 1821408188
$7,270.88
in general payments reported to CMS, 2019-2025
41 companies · $15.08 in 2025
The $15.08 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $993 · 2021: $1,711 · 2022: $2,477 · 2023: $768 · 2024: $40.61 · 2025: $15.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,616.17 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $649.77 | 2020-2023 | Repatha, Prolia, Evenity |
| Corcept Therapeutics | $490.04 | 2019-2023 | Korlym |
| Lilly USA, LLC | $383.38 | 2019-2023 | Jardiance, Lyumjev, Baqsimi |
| Cequr Corporation | $331.29 | 2022-2023 | Cequr Simplicity |
| Abbott Laboratories | $323.47 | 2020-2022 | |
| Radius Health, INC. | $281.54 | 2021-2023 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $279.15 | 2019-2022 | |
| Dexcom, INC. | $277.89 | 2021-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.43 | 2020-2022 | |
| Companion Medical, INC. | $194.97 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $174.26 | 2019-2022 | |
| Horizon Therapeutics Plc | $158.09 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.08 | 2021-2022 | |
| Esperion Therapeutics, INC. | $155.60 | 2020-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $138.31 | 2022-2023 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $130.04 | 2020-2022 | |
| Mannkind Corporation | $123.26 | 2021-2022 | |
| Insulet Corporation | $105.68 | 2021-2023 | Omnipod |
| Veloxis Pharmaceuticals, INC. | $102.33 | 2022-2024 | Envarsus |
| Zealand Pharma US, INC. | $88.07 | 2020-2022 | |
| Amryt Pharma Holdings LTD | $87.09 | 2022-2023 | Mycapssa |
| Antares Pharma, INC. | $80.24 | 2020-2023 | Nocdurna, Xyosted, Tlando |
| Tandem Diabetes Care, INC. | $79.57 | 2020-2022 | |
| Intuity Medical INC | $78.56 | 2022 | |
| Eusa Pharma (US) LLC | $76.76 | 2022 | |
| Alexion Pharmaceuticals, INC. | $66.35 | 2021-2023 | Strensiq |
| Amneal Pharmaceuticals LLC | $55.84 | 2020-2023 | Unithroid |
| Nevro Corp. | $53.45 | 2021-2023 | Senza |
| Ultragenyx Pharmaceutical INC. | $42.55 | 2021 | |
| Calliditas Therapeutics US INC. | $35.16 | 2023 | Tarpeyo |
| Abbvie INC. | $31.56 | 2023 | |
| Astellas Pharma US INC | $28.95 | 2023-2025 | Veozah, Myrbetriq |
| Ani Pharmaceuticals, INC. | $27.42 | 2022 | |
| Acerus Pharmaceuticals Corporation | $18.27 | 2020 | |
| Amarin Pharma, INC. | $18.15 | 2022 | |
| Beta Bionics, INC. | $17.26 | 2023 | Ilet Bionic Pancreas |
| Merck Sharp & Dohme LLC | $13.48 | 2019 | |
| Vivus LLC | $13.35 | 2021 | |
| Pfizer INC. | $12.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.